ARID1A and neoplasm: This heterogeneity might be partly due to various geographic populations, study design, sample size, different tumor staging, gender, age, and the assessments for the expression level of ARID1A. Third, the biomarker role, the potential antitumor effect, and the underlying biological mechanisms for the participation of ARID1A variants in the tumorigenesis of CRC, development, prediction, and therapy need to be further studied.